Saliva as Alternative Abogen has validated saliva as a viable substitute for blood in cell-based research and diagnostics, presenting a potential market expansion opportunity to labs and clinics seeking less invasive sample collection.

mRNA Vaccine Focus With past and ongoing engagement in mRNA vaccine development for Covid-19 and dengue, there are clear collaboration channels for partnerships in vaccine research, manufacturing, and distribution with biotech firms and contract research organizations.

Strategic Partnerships Recent provisional collaborations with CanSino, Walvax, and Abogen for inhalable vaccines and viral-vector facilities indicate a network-ready approach; leverage these ties to propose co-development, licensing, or funded research opportunities.

Funding Momentum A significant Series C funding round underscores investor confidence and potential for capital-backed initiatives; target customers and partners may be open to joint ventures, pilot programs, or early-access services aligned with their portfolio growth.

Early-Stage Scale Potential Small team size (2-10 employees) coupled with a biotechnology focus suggests opportunities to offer scalable CRO/CMC support, regulatory consulting, and enterprise-grade collaboration tools to accelerate research timelines.